Letter re: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis
| Autor: | Floyd A. Davis |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Multiple Sclerosis business.industry Mechanism (biology) Multiple sclerosis medicine.disease Term (time) 03 medical and health sciences 0302 clinical medicine Physical medicine and rehabilitation Gait (human) Humans Medicine 030212 general & internal medicine Neurology (clinical) 4-Aminopyridine business Gait 030217 neurology & neurosurgery |
| Zdroj: | Neurology. 89:1199.2-1199 |
| ISSN: | 1526-632X 0028-3878 |
| DOI: | 10.1212/wnl.0000000000004376 |
| Popis: | I read the article by Filli et al.1 with great interest. The authors reported that the responsiveness (efficacy) of prolonged-release fampridine for improving walking in multiple sclerosis (MS) increases over time.1 While the underlying mechanism is not known, its understanding might provide important insight for enhancing the efficacy of fampridine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|